{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.37","upperLimit":"0.53","value":"0.45"},{"groupId":"OG001","lowerLimit":"0.76","upperLimit":"1.01","value":"0.88"},{"groupId":"OG002","lowerLimit":"0.54","upperLimit":"0.77","value":"0.66"},{"groupId":"OG003","lowerLimit":"0.20","upperLimit":"0.29","value":"0.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"59"}],"units":"Participants"}],"title":"Last 48 hours"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.12","upperLimit":"0.19","value":"0.16"},{"groupId":"OG001","lowerLimit":"0.28","upperLimit":"0.39","value":"0.33"},{"groupId":"OG002","lowerLimit":"0.35","upperLimit":"0.59","value":"0.47"},{"groupId":"OG003","lowerLimit":"0.07","upperLimit":"0.13","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"title":"Last 72 hours"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"59"}],"units":"Participants"}],"description":"Serum asparaginase levels serve as a surrogate marker for asparagine depletion. Mean serum asparaginase activity levels in Course 1 are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks based on available data from the Phase 1 (JZP458-101) healthy volunteer study.","id":"OG000","title":"Part A: JZP-458 IM 25 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 37.5 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG001","title":"Part A: JZP-458 IM 37.5 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG002","title":"Part A: JZP-458 IM 25 (MW)/50 mg/m^2 (F)"},{"description":"Participants who received an intravenous (IV) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG003","title":"Part B: JZP-458 IV 25 (MW)/50 mg/m^2 (F)"}],"paramType":"MEAN","populationDescription":"Serum asparaginase activity levels were assessed in participants with available data in the Efficacy Analysis Set.","reportingStatus":"POSTED","timeFrame":"Up to 2 weeks (6 doses)","title":"Mean Serum Asparaginase Activity Levels in First Course of JZP-458 Administration","type":"SECONDARY","unitOfMeasure":"IU/mL"}